WO2005024004A1 - 間葉系幹細胞の肝細胞への分化方法及び人工ヒト肝臓細胞 - Google Patents
間葉系幹細胞の肝細胞への分化方法及び人工ヒト肝臓細胞 Download PDFInfo
- Publication number
- WO2005024004A1 WO2005024004A1 PCT/JP2004/002440 JP2004002440W WO2005024004A1 WO 2005024004 A1 WO2005024004 A1 WO 2005024004A1 JP 2004002440 W JP2004002440 W JP 2004002440W WO 2005024004 A1 WO2005024004 A1 WO 2005024004A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- mesenchymal
- liver
- mesenchymal stem
- stem cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
Definitions
- the present invention relates to a technique for differentiating mesenchymal cells into hepatocytes.
- the present invention further relates to a liver regeneration medical technology for animals including a liver-damaged person.
- the liver also called the biochemical factory of the human body, is an important organ that has various biochemical functions such as intermediate metabolism, bile formation, blood component production / conversion, and detoxification, which are closely related to nutrition in the body.
- liver is damaged by alcohol, viruses, drugs, or autoimmune diseases, hepatitis, and even cirrhosis, sometimes with serious consequences.
- alcoholic liver injury chronic overdose of alcoholic beverages causes damage to liver cells, leading to fatty liver, alcoholic hepatitis, and even terminal cirrhosis. If the amount of alcohol consumed daily is 60-80 g or more, fatty liver is more likely to occur, and if alcohol consumption of 100-120 g or more per day is taken for 10 years or more, cirrhosis is said to occur. ing.
- liver injury Conventional treatments for liver injury include (1) eliminating toxic substances such as alcohol that cause liver injury, (2) waiting for spontaneous regeneration of hepatocytes by supplementing vitamins, etc. (3) Treatment with drugs (I) Glycyrrhizin preparation (protects the function of the liver), (ii) Sho-saiko-to (reducing liver inflammation, improving liver function), (iii) Bile acid preparation (useful for liver damage due to gallstones and bile stasis), (4 ) Therapeutic agents for viral hepatitis include (i) interferon,
- Rebetol combined use with antivirals and interferon: for chronic hepatitis C with large viral load
- Lamivudine antivirals, hepatitis B, DNA polymerase inhibitor
- Non-Patent Document 1 shows that the alkaline phosphatase-positive rat stem cell-like cell line was differentiated into a hepatocyte lineage in vitro. Is reported in Non-Patent Document 2.
- Patent Document 1 describes that bone marrow cells are differentiated into hepatic parenchymal cells using a differentiation inducer.
- Patent Document 1 Japanese Patent Application Publication No. 2000--7 8 4 8 2
- Non-Patent Document 1 Stem Cel ls Vol. 21, .428-436
- Non-Patent Document 2 The Journal of Clinical Investigation, Vol. 109, p. 1291-1302
- Hepatic pharmacotherapy is only a symptomatic treatment and is not sufficient.
- hepatocytes and MAPCs multipotent adult progenitor cells
- MAPCs multipotent adult progenitor cells
- hepatocytes are differentiated into hepatocytes using mesenchymal stem cells for which proliferation techniques have been established, especially stromal cells, which are mesenchymal stem cells derived from bone marrow. It is an object to provide a means for preparing cells.
- mesenchymal stem cells mesenchymal progenitor cells or mesenchymal cells
- mesenchymal progenitor cells or mesenchymal cells By transplanting mesenchymal stem cells, mesenchymal progenitor cells or mesenchymal cells into a mammal that has chronic liver injury caused by continuing drug administration, for example, into a rat liver, hepatocytes, They found that they differentiate into mature hepatocytes, and developed a means to differentiate mesenchymal stem cells, mesenchymal progenitor cells or mesenchymal cells into mature hepatocytes.
- mature hepatocytes can be prepared using mesenchymal stem cells, mesenchymal progenitor cells or mesenchymal cells that are available in a sufficient amount.
- hepatocytes can be differentiated from mesenchymal stem cells, mesenchymal progenitor cells or mesenchymal cells prepared from an individual, and an individual-specific hepatocyte gene profile can be created, which will be useful for tiller-made medicine You can also.
- hepatocytes can be prepared in large amounts, they can be used for analysis of the proliferation mechanism of hepatitis C virus and hepatitis B virus, and also for analysis of the mechanism of action of antiviral agents.
- Figure 1 shows the preparation of human mesenchymal stem cells.
- Figure 2 shows how to administer allylic alcohol, which causes chronic liver damage.
- FIG. 3 shows antibody staining 14 days after transplantation of human mesenchymal stem cells
- FIG. 4 shows antibody staining 28 days after transplantation of human mesenchymal stem cells
- Figure 5 shows the expression of human albumin in rat liver transplanted with human mesenchymal stem cells.
- Figure 6 shows the expression of human alpha-phytoprotein in rat liver transplanted with human mesenchymal stem cells
- Figure 7 shows the human albumin production
- Figure 8 shows that human mesenchymal stem cells, human CD34 + cells or non-mesenchymal cells Z non-CD34 + cells were treated once or continuously with aryl alcohol to human hepatocytes.
- Fig. 9 shows the hepatic differentiation of human mesenchymal hepatocytes (MSCs) transfected with TERT (hepatic differentiation of MSCs transfected with TERT).
- the present invention provides a method for transplanting a mesenchymal stem cell (Mesenchymal Stem Cell; also referred to as MSC), a mesenchymal progenitor cell or a mesenchymal cell into a mammal suffering from chronic liver damage by continuing drug administration.
- MSC mesenchymal Stem Cell
- a mesenchymal progenitor cell or a mesenchymal cell into a mammal suffering from chronic liver damage by continuing drug administration.
- mesenchymal stem cells, mesenchymal progenitor cells or mesenchymal cells into a mammal having acute hepatic injury, and to continuously administer a hepatotoxic agent after the transplantation. It is intended to provide a method for making liver damage chronic and differentiating transplanted mesenchymal stem cells, mesenchymal progenitor cells or mesenchymal cells into mature hepatocytes.
- Mesenchymal stem cells, mesenchymal progenitor cells or mesenchymal cells can be derived from any mammal. Although mesenchymal stem cells, mesenchymal progenitor cells or mesenchymal cells can be used, preferred examples include humans, mice, rats, monkeys, and the like, which are commonly used as experimental animals.
- mesenchymal stem cells for example, bone marrow, peripheral blood, skin, hair root, muscular tissue, endometrium, blood, umbilical cord blood, and stem cells obtained from an initial culture of various tissues are used. be able to. It is also known that mesenchymal stem cells can be separated from ES cells and teratoma cells.
- a stem cell is a totipotent stem cell capable of differentiating into all totipotent cells, or is capable of differentiating into three germ layers such as fetal stem cells, but is limited to extraembryonic trophoblast cells
- pluripotency stem cells and pluripotent stem cells that can differentiate into many cells of a certain tissue.
- Mesenchymal stem cells are considered to be pluiripotent.
- stem cells obtained by performing initial culture of bone marrow and obtaining from stromal cells attached to the bottom of the culture dish can be preferably used.
- the precursor cells of mesenchymal cells refer to cells that are differentiated from mesenchymal stem cells and are in the process of differentiation into mesenchymal cells.
- Mesenchymal cells are cells that arise from the differentiation of mesenchymal stem cells and do not have the ability to differentiate in many ways as stem cells do, but have the ability to differentiate and proliferate in certain directions. These cells are normally in the G0 phase, but can enter the G1 phase (start of division) upon stimulation. Mesenchymal cells also include, for example, stromal cells and cells having stromal cell properties. Mesenchymal cells are present in all organs, such as subcutaneous tissue, lungs, and liver, and are present in mesenchymal tissues such as bone, cartilage, fat, tendons, skeletal muscle, and bone stromal tissue.
- an immortalizing gene for example, a gene that regulates the expression or activity of telomerase or telomerase, preferably human telomerase or a human telomerase catalytically active subunit (hTERT), is used for immortalization.
- telomerase or telomerase preferably human telomerase or a human telomerase catalytically active subunit (hTERT)
- hTERT human telomerase catalytically active subunit
- the immortalizing gene is incorporated into a plasmid vector, and the vector is replaced with calcium-phosphate Stroma in the presence of Transformation by introducing into mesenchymal cells such as cells, mesenchymal stem cells, etc., or contacting the immortalizing gene with mesenchymal cells or mesenchymal stem cells together with vesicles such as ribosomes
- An introduction method can be used.
- a method for introduction using a virus vector there is a method using a retrovirus, an adenovirus, or an adeno-associated virus.
- a retrovirus vector a method using a MoMLV virus is used.
- a pBabe vector can be used.
- the immortalized gene can be removed.
- bone marrow-derived mesenchymal stem cells can be suitably used.
- mesenchymal stem cells will be described.
- mesenchymal progenitor cells and mesenchymal cells can also similarly differentiate into hepatocytes.
- a mammal for providing a chronic liver injury tissue that provides an effective environment for differentiation of mesenchymal stem cells into hepatocytes
- various experimental animals can be used.
- mouse, SCID mouse, rat and the like can be preferably used, and SD rat can be used particularly preferably.
- the rat it is preferable that the rat is as young as possible, for example, 4 to 6 weeks old.
- hepatotoxic drug various drugs that cause hepatic impairment can be used.
- allylic alcohol Allyl Alcohol
- carbon tetrachloride CC14
- carbon tetrachloride CC14
- 2-acetylaminoiluorene 2-AAF
- AAF can be used, and it is particularly preferable to use allyl alcohol.
- Aryl alcohol has the effect of damaging hepatocytes, especially around the portal vein, by necrosis.
- an immunosuppressant is preferably added in advance to reduce the immune response in the transplantation. It is desirable to administer to animals to be transplanted 2 to 2 days before.
- a method for transplantation into an animal to be transplanted for example, local injection, intraportal injection, or tail vein injection of a mesenchymal cell-containing solution into the liver of the above-mentioned animal can be employed.
- the timing of transplantation of mesenchymal stem cells may be affected by the hepatopathy drug.Therefore, at least 24 hours after administration of the first hepatopathy drug to the target animal It can be transplanted within three days, preferably one day later.
- livers that already have chronic liver damage such as the liver of LEC rats, which is a model for cirrhosis of Wilson's disease, or FAH-/-mice, which have liver damage due to hypertyrosinemia.
- liver disorder chronic in the transplantation target animal there is a method of transplanting the mesenchymal stem cells into the transplantation target animal and then continuing to administer the hepatopathy drug to make the liver damage chronic.
- the dose of the hepatotoxic drug can be selected to be sufficient to cause acute damage to the liver but not to affect the survival of the animal in the first dose, for example, When aryl alcohol is used in the rat, an amount of about 0.5 mm o 1 Kg to about 0.7 mm o 1 / K g, preferably about 0.6 mm o 1 ZK g can be used. Wear. In the second and subsequent doses, the hepatotoxic drug can be used in an amount sufficient to make the hepatic disorder chronic.For example, when using allylic alcohol, 0.3 mm o 1 / Kg can do.
- a suitable administration method can be selected depending on the drug.
- oral administration, intravenous injection, or intraperitoneal injection can be used, and when alcohol is administered to a rat.
- Can preferably be by intraperitoneal injection can be used.
- the number of mesenchymal stem cells required to differentiate into mature hepatocytes is, for example, 2 weeks to 3 months, preferably 3 to 5 weeks, more preferably 4 weeks. it can.
- the number of mesenchymal stem cells required to differentiate into mature hepatocytes is, for example, 2 weeks to 3 months, preferably 3 to 5 weeks, more preferably 4 weeks. it can.
- intraperitoneal injection of 0.3 mmo1 / kg should be continued three times a week for one month Can be.
- Markers (labels) for undifferentiated hepatocytes include GST_P, cytokeratin 19, and a-fetoprotein. Detection of these markers requires the use of antibodies against these antibodies. Or a gene-specific primer or probe encoding a marker can be used. Furthermore, undifferentiated hepatocytes (immature hepatocytes) can also be differentiated by GTP staining.
- Markers (labels) for mature hepatocytes include albumin, ⁇ -antitrypsin, transferrin, CK18, AGPR, and the like. These markers are antibodies against the markers, gene-specific primers encoding the markers, or gene-specific primers. It can be detected using a single probe.
- anti-albumin antibody anti-AFP (human protein) antibody
- anti-CK19 antibody anti-CK19 antibody
- anti-CK18 antibody anti-AGPR antibody
- AGPR is By comparing the reactivity with lycoprotein receptor, such as ialoglycoprote in receptor, the same shall apply hereinafter.
- the mesenchymal stem cells are transplanted into the liver of an animal different from the animal from which the mesenchymal stem cells are derived, for example, when the human mesenchymal stem cells are transplanted into a rat liver-impaired liver, the mesenchymal stem cells Animal specific origin of origin It can be confirmed by immunostaining, immunoenzymatic staining, sandwich antibody method and the like using the above-mentioned antibody specific to mature hepatocyte marker and human albumin-specific antibody.
- a marker-specific primer When a marker-specific primer is used, a gene amplification method, for example, PCR can be used. [Recovery of differentiated hepatocytes]
- a liver is removed from an experimental animal, separated into hepatocytes, and a fluorescently labeled antibody or cell surface marker that is specific to the animal from which the mesenchymal cells are derived and specific to the mature hepatocyte
- -Mature hepatocytes differentiated from mesenchymal stem cells can be isolated by treating with antibodies against HLA (such as HLA) and using a fluorescent cell sorter (FACS).
- HLA such as HLA
- FACS fluorescent cell sorter
- telomere Human telomerase is introduced, and immortalized TERT-introduced MSCs are differentiated into the liver by the method described above, and the perfused cells are cultured. Since hepatocytes derived from rats usually die in about one week, the remaining cells are mature hepatocytes differentiated from mesenchymal stem cells. This is cultured and propagated in an appropriate medium.
- Hepatocytes differentiated from mesenchymal stem cells prepared from individuals can be collected, and individual-specific hepatocellular gene profiles can be created, which can be useful for tiller-made medicine.
- hepatocytes can be prepared in large quantities, they can be used for analysis of the proliferation mechanism of hepatitis C virus and hepatitis B virus, and also for analysis of the mechanism of action of antiviral agents.
- a large amount of human normal mature hepatocytes that could not be obtained conventionally can be obtained, they can be used for drug screening and drug toxicity tests.
- the isolated and recovered human hepatocytes can be used for cell therapy transplantation to patients with liver failure and congenital metabolic liver disease or for the production of artificial liver.
- mesenchymal stem cells can be used as a cell therapeutic agent to be directly administered to a liver disease site together with a suitable carrier for cell therapy of chronic hepatitis.
- Example 1 is merely examples of the present invention, and the present invention is not limited to the examples.
- Example 1 is merely examples of the present invention, and the present invention is not limited to the examples.
- MSC Mesenchymal stem cells
- Bone marrow puncture was performed from the iliac bone of a healthy adult, mononuclear cells were collected by specific gravity centrifugation, and cultured overnight in DMEM containing 10% inactivated fetal serum. From the next day, adherent cells (adherent cells) Incubate. Two weeks later, cells recovered by T_E (trypsin-EDTA) were used as primary mesenchymal stem cells and cryopreserved. Primary cultures of mesenchymal stem cells were subcultured in DMEM containing 10% inactivated fetal serum and PD 6 to 9 (from 6 to 9 generation division doublings) from the primary culture. Used for experiments ( Figure 1).
- Spragne-Dawley (SD) rats (five weeks old, female or male) purchased from Charles River Japan were used.
- mice On the 14th (day 14) and the 28th (day 28) after MSC administration, the mice were sacrificed, and the liver was perfused and fixed with 4% paraformaldehyde, embedded with an OTC compound, and frozen sections (6 zm) were prepared.
- Anti-human Alb (albumin) antibody Sigma, A6684
- anti-human AFP antibody Sigma, A8452
- anti-human CK19 antibody Sigma, C6930
- Immunostaining was performed using anti-human CK18 antibody (PROGEN, RCK106), AGPR antibody (Kohgo et al., Hybridoma 1993; 12.591-598) and control antibody.
- Figure 3 shows the results at 14 times after MSC transplantation at 400x magnification.
- Fig. 3 Upper and middle sections As shown, about 50 to 80 positive cells of anti-human AFP antibody, anti-human CK19 antibody, anti-human Alb antibody, anti-human CK18 antibody, or anti-AGPR antibody with a diameter of about 20-25 mm on the same section. In the form of clusters. No staining was observed with the control antibody. In the fluorescent immunostaining shown in the lower part, staining was carried out with the rhodamine (Rodamine) -labeled anti-human AFP antibody (left) shown in red and the FI-labeled anti-human Alb antibody (middle) shown in green, and a superposition of these was shown on the right. These merged MSCs were considered to express AFP and Alb, since they appeared yellow in the merged image. These staining patterns indicate relatively undifferentiated human hepatocytes.
- Rodamine rhodamine
- Figure 4 shows the results of immunostaining 28 days after MSC transplantation. As in the 14th day, the magnification was 400 times, but as shown in the upper and middle panels, positive cells of anti-human Alb antibody, anti-human CK18 antibody or anti-human CK18 antibody or AGPR antibody with a diameter of 25-30 were found on the same section. More than 300 clusters were observed in one pattern. On the other hand, positive cells with anti-human AFP antibody or anti-human CK19 antibody were only slightly scattered. In the fluorescent immunostaining shown in the lower part, similarly, redamine-labeled anti-human AFP antibody-positive cells, also shown in red, were partially observed, and the whole cells were stained with FITC-labeled anti-human Alb antibody (center). In the merged image shown on the right, the AFP antibody-positive cells appear to be yellow, indicating that most of these transplanted MSCs express Mb but partially retain AFP expression. These staining patterns indicate mature human hepatocytes.
- Primer sequence includes primer sense strand for human albumin
- Fig. 5 where the expression of Alb was examined, 1; HepG2 cells, which are hepatocellular carcinoma cells (positive control), 2; rat liver (negative control), 3; , 4; AA administration of CD34 + cells as a control three times a week after hepatic administration, and 5; Non-MSC / non-CD34 + cells as a control excluding MSC and CD34 were injected three times a week. 6 times AA administration, 6; MSC administered only once after hepatic injection of MSC, 7; control CD34 + cells administered once AA after hepatic injection, and 8; MSC as control And Non-MSC / non-CD34 + cells excluding CD34 were injected with AA only once after hepatic injection. On the 14th day (Day 14) and the 28th day (Day 28) after MSC administration, human Alb band was shown only when AA was administered three times a week after MSC hepatic administration.
- AFP expression was examined, 1; HepG2 cells, a liver cancer cell (positive control), 2; rat fetal liver (negative control), 3; MSC were injected AA three times a week after hepatic administration. 4; weekly after injection of AA three times a week after injection of CD34 + cells as a control, and 5 weeks after injection of non-MSC / non-CD34 + cells excluding MSC and CD34 as control Three AA administrations, 6; MSCs injected only once after hepatic injection, 7; Controls CD34 + cells injected once only after AA administration, and 8; Controls Non-MSC / non-CD34 + cells excluding MSC and CD34 were injected into the liver and injected with AA only once. On day 14, only human AFP was administered three times a week after MSC hepatic injection, and a human AFP band was shown.
- Fig. 7 in which Alb production was examined, from the right, 1; human liver tissue (positive control), 2; rat liver (negative control), 3; MSA administered to the liver station three times a week after AA administration , 4; AA administration three times a week after CD34 + cells were injected into the liver as a control, and 5; Non-MSC / non-CD34 + cells excluding MSC and CD34 were injected into the liver three times a week.
- Human Alb production was 4 ng / mg of t issue / ml on the 14th day after transplantation, and 7.6 ng / mg of t issue / ml in liver tissue 28 days after the transplantation in MSC-transplanted AA continuous administration hepatic disorder rats And human Alb production, which increased significantly compared to other controls and were close to human liver tissue.
- liver differentiation of MSC was shown in a chronic liver injury model in which AA was administered three times a week, not in the acute hepatitis group. This suggests that AA-induced persistent liver injury is an environment suitable for inducing differentiation of MSCs into liver.
- liver differentiation was not observed in any liver injury model.
- HSC Hematopoietic Stem Cell
- bone marrow cells were used. This is considered to be the result that it is necessary to remove bone marrow cells by radiation (rad iaton) for hepatic differentiation to allow transplanted cells to survive in the bone marrow.
- an MSC (TERT-MSC) into which the prepared hTERT was introduced was prepared by the method described in Reference Example 1 below. Observation was performed 28 days after local injection into the liver. As a result, as shown in FIG. 9, cells expressing human albumin were confirmed in normal rat liver tissue, and it was considered that the cells had differentiated into mature hepatocytes.
- Rats in which the hTERT gene-derived mesenchymal stem cell-derived (hTERT-MSC) was locally injected into the liver were shaved under deep anesthesia 28 days after the local injection, followed by laparotomy.
- Perfuse 37 ° C EGTA solution (adjusted with Hanks solution 500 mL + HEPES 1.19 g + EGTA 0.1 lg) from the portal vein. After confirming swelling of the liver, cut the inferior vena cava above and below the liver and perfuse at a rate of 10 mL / min for 10 minutes.
- the collagenase solution ((Hanks solution 500 mL + CaC12 / 2H20
- rat hepatocytes die in about one week, they are observed for about one week, and hTERT-MSC-derived human hepatocytes form colonies.
- hTERT A gene encoding the catalytic subunit of human telomerase (hTERT) was used as a gene to be introduced into mesenchymal stem cells. The sequence of MERT is described, for example, in Science 277, ⁇ ⁇ 955-959.
- pBABE-hygro-hTERT (provided by Dr. Robert A Weinberg), pBABE-hygro-hTERT is pCI-Neo as described in Pro Natl. Acad. Sci. USA vol. -hTERT EcoRV-Sall fragment obtained by PCR from hTERT-HA was cloned into BABE-hygro.
- Solution A was gently mixed with solution B to prepare solution C, which was left at room temperature for 30 to 45 minutes.
- the above vector was propagated in retrovirus-producing cells (CRIP / P131), and mesenchymal stem cells were transfected (infected) as follows.
- the mesenchymal stem cells 5xl0 4 cel l / l O cm dish and so as to re-sown the medium producing Suruyu CRIP / P131 retrovirus 10% ⁇ shea serum-containing DMEM or al 12. 5% inactivated fetal serum 12.5% inactivated fetal serum / containing 2-mercaptoethanol / ydrocorto isone-Incubate instead of -MEM medium.
- the culture supernatant was filtered through a 0.20 m filter, and polybrene was added to a final concentration of 8 / ml.
- mesenchymal stem cells were infected with the recombinant retrovirus vector produced in the supernatant.
- the retrovirus vector was infected with only (1) the control and (2) the pBABE-hygro-hTERT vector alone.
- the present invention can be used in industries such as cell differentiation, cell culture, drug development, and artificial organ development, and can also be used in the industrial field related to liver regeneration medical technology.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physiology (AREA)
- Developmental Biology & Embryology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002536934A CA2536934A1 (en) | 2003-08-27 | 2004-02-27 | Method for differentiating mesenchymal stem cell into hepatocyte and artificial human hepatocyte |
EP04715554A EP1669441A1 (en) | 2003-08-27 | 2004-02-27 | Method of differentiating mesenchymal stem cell into liver cell and artificial human liver cell |
JP2005513583A JPWO2005024004A1 (ja) | 2003-08-27 | 2004-02-27 | 間葉系幹細胞の肝細胞への分化方法及び人工ヒト肝臓細胞 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003303229 | 2003-08-27 | ||
JP2003-303229 | 2003-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005024004A1 true WO2005024004A1 (ja) | 2005-03-17 |
Family
ID=34269196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/002440 WO2005024004A1 (ja) | 2003-08-27 | 2004-02-27 | 間葉系幹細胞の肝細胞への分化方法及び人工ヒト肝臓細胞 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1669441A1 (ja) |
JP (1) | JPWO2005024004A1 (ja) |
KR (1) | KR20060065712A (ja) |
CA (1) | CA2536934A1 (ja) |
WO (1) | WO2005024004A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009506770A (ja) * | 2005-09-02 | 2009-02-19 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 前駆細胞株の誘導法 |
JP2012120486A (ja) * | 2010-12-08 | 2012-06-28 | Kinki Univ | 免疫不全動物を用いた細胞の製法 |
CN105051023A (zh) * | 2013-03-15 | 2015-11-11 | 豪夫迈·罗氏有限公司 | 促进干细胞分化为肝细胞的化合物 |
CN111849880A (zh) * | 2020-06-23 | 2020-10-30 | 和携科技有限公司 | 一种人脂肪间充质干细胞超低温冻存后的复苏方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2578081B1 (en) * | 2006-10-11 | 2016-03-09 | The General Hospital Corporation | Compositions, methods, and devices for treating liver disease |
WO2008085229A2 (en) * | 2006-11-15 | 2008-07-17 | Arteriocyte Inc. | Cell-based therapies for treating liver disease |
WO2009072990A1 (en) | 2007-12-06 | 2009-06-11 | Agency For Science, Technology And Research | Method for extracellular matrix mediated differentiation and proliferation of stem cells |
WO2014132129A2 (en) * | 2013-01-08 | 2014-09-04 | Pharmicell Co., Ltd. | Autologous bone-marrow-derived mesenchymal stem cells for alcoholic cirrhosis |
US9816074B2 (en) | 2014-07-25 | 2017-11-14 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
EP3006557A1 (en) * | 2014-10-07 | 2016-04-13 | Heinrich-Heine-Universität Düsseldorf | Bile acids for inducing hepatic differentiation |
US20230020486A1 (en) * | 2019-12-19 | 2023-01-19 | University Of Miami | Stem Cell Delivery |
-
2004
- 2004-02-27 WO PCT/JP2004/002440 patent/WO2005024004A1/ja not_active Application Discontinuation
- 2004-02-27 JP JP2005513583A patent/JPWO2005024004A1/ja active Pending
- 2004-02-27 EP EP04715554A patent/EP1669441A1/en not_active Withdrawn
- 2004-02-27 KR KR1020067003864A patent/KR20060065712A/ko not_active Application Discontinuation
- 2004-02-27 CA CA002536934A patent/CA2536934A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
ALISON M R, ET AL: "Hepatocytes from non-hepatic adult stem cells", NATURE, vol. 406, 2000, pages 257, XP002195493 * |
BARRY F P, ET AL: "Biology and clinical applications of mesenchymal stem cells", BIRTH DEFECTS RESEARH PART C, vol. 69, 25 August 2003 (2003-08-25), pages 250 - 256, XP002976497 * |
PETERSEN B E, ET AL: "Bone marrow as a potential source of hepatic oval cells", SCIENCE, vol. 284, 1999, pages 1168 - 1170, XP002147735 * |
TUAN R S, ET AL: "adult mesenchymal stem cells and cell-based tissue engineering", ARTHRITIS RESEARCH AND THERAPY, vol. 5, no. 1, 2002, pages 32 - 45, XP002976496 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009506770A (ja) * | 2005-09-02 | 2009-02-19 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 前駆細胞株の誘導法 |
JP2012120486A (ja) * | 2010-12-08 | 2012-06-28 | Kinki Univ | 免疫不全動物を用いた細胞の製法 |
CN105051023A (zh) * | 2013-03-15 | 2015-11-11 | 豪夫迈·罗氏有限公司 | 促进干细胞分化为肝细胞的化合物 |
CN111849880A (zh) * | 2020-06-23 | 2020-10-30 | 和携科技有限公司 | 一种人脂肪间充质干细胞超低温冻存后的复苏方法 |
CN111849880B (zh) * | 2020-06-23 | 2022-04-29 | 和携科技有限公司 | 一种人脂肪间充质干细胞超低温冻存后的复苏方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1669441A1 (en) | 2006-06-14 |
KR20060065712A (ko) | 2006-06-14 |
CA2536934A1 (en) | 2005-03-17 |
JPWO2005024004A1 (ja) | 2006-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2432744T3 (es) | Células del tejido adiposo extramedular y sus aplicaciones en la reconstitución del tejido cardiaco | |
KR101507174B1 (ko) | 면역 특권 및 조절 전구 세포 | |
Halabian et al. | Lipocalin-2-mediated upregulation of various antioxidants and growth factors protects bone marrow-derived mesenchymal stem cells against unfavorable microenvironments | |
Watanabe et al. | Establishment of immortalized human hepatic stellate scavenger cells to develop bioartificial livers1 | |
EP1447443A1 (en) | Immortalized mesenchymal cells and utilization thereof | |
WO2005024004A1 (ja) | 間葉系幹細胞の肝細胞への分化方法及び人工ヒト肝臓細胞 | |
CN114423860A (zh) | 包含病毒载体的细胞组合物及治疗方法 | |
CN104845932A (zh) | 淫羊藿苷的新用途 | |
EP2690174B1 (en) | Method for producing epithelial stem cells | |
Dai et al. | Induction of Functional Hepatocyte-Like Cells by Overexpression of FOXA3 and HNF4α in Rat Bone Marrow Mesenchymal Stem Cells | |
US20220233665A1 (en) | Medicinal composition | |
JP4118236B2 (ja) | 中胚葉幹細胞もしくはes細胞、または不死化した中胚葉幹細胞から神経系細胞への分化誘導方法 | |
CN109749981B (zh) | 人源脂肪干细胞来源的肝细胞样细胞及其制备方法和应用 | |
KR20210116469A (ko) | Hla-e를 발현하는 간 전구 세포를 포함하는 세포 조성물 | |
TWI374188B (en) | Liver stromal cells for prevention and treatment of immune responses in transplantation | |
JP3898467B2 (ja) | ヒト臍帯血有核細胞由来の肝細胞 | |
CN111849859A (zh) | 一种经基因编辑的功能性肝实质细胞的制备方法及其应用 | |
KR102233568B1 (ko) | 항암 바이러스가 도입된 중간엽 줄기세포의 세포 생존능을 향상시키는 방법 | |
JP2010051326A (ja) | 中胚葉幹細胞を神経系細胞に分化誘導する方法 | |
US20190224243A1 (en) | Enhancement of the Beneficial Effects of Mesenchymal Stem Cell Treatment by the Caveolin-1 Scaffolding Domain Peptide and Subdomains | |
JP2023001294A (ja) | 臓器線維症の予防または治療剤 | |
KR20190142266A (ko) | 항암 바이러스가 도입된 중간엽 줄기세포의 세포 생존능을 향상시키는 방법 | |
TW201114895A (en) | Treatment using reprogrammed mature adult cells | |
JP2008119003A (ja) | 中胚葉幹細胞もしくはes細胞、または不死化した中胚葉幹細胞から神経系細胞への分化誘導方法 | |
KR20200047096A (ko) | 역분화 만능 유도세포 유도용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005513583 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2536934 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067003864 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004715554 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004715554 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004715554 Country of ref document: EP |